Nanoparticles (NPs) administered in the human body will undergo rapid surface modification upon contact with biological fluids driven by their interfacial interaction with a diverse range of biomolecules. Such spontaneous self-assembly and adsorption of proteins and other biomolecules onto the NP surface constitute what is commonly known as the protein or biomolecule corona. This surface biotransformation of the NPs modulates their biological interactions and impact on physiological systems and can influence their overall pharmacological profile. Here, we comment on how the initially considered ‘nuisance’ of the in vivo corona formation can now be considered a nanoparticle engineering tool for biomedical use, such as in endogenous tissue targeting, personalized biomarker discovery and immunomodulation.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Mahmoudi, M., Landry, M. P., Moore, A. & Coreas, R. The protein corona from nanomedicine to environmental science. Nat. Rev. Mater. 8, 422–438 (2023).
Sakulkhu, U. et al. Ex situ evaluation of the composition of protein corona of intravenously injected superparamagnetic nanoparticles in rats. Nanoscale 6, 11439–11450 (2014).
Hadjidemetriou, M. et al. In vivo biomolecule corona around blood-circulating, clinically used and antibody-targeted lipid bilayer nanoscale vesicles. ACS Nano 9, 8142–8156 (2015).
Hadjidemetriou, M. et al. The human in vivo biomolecule corona onto pegylated liposomes: a proof-of-concept clinical study. Adv. Mater. 31, 1803335 (2019).
Vu, V. P. et al. Immunoglobulin deposition on biomolecule corona determines complement opsonization efficiency of preclinical and clinical nanoparticles. Nat. Nanotechnol. 14, 260–268 (2019).
Gardner, L. et al. The biomolecule corona of lipid nanoparticles contains circulating cell-free DNA. Nanoscale Horiz. 5, 1476–1486 (2020).
Mahmoudi, M. The need for improved methodology in protein corona analysis. Nat. Commun. 13, 49 (2022).
Dilliard, S. A. & Siegwart, D. J. Passive, active and endogenous organ-targeted lipid and polymer nanoparticles for delivery of genetic drugs. Nat. Rev. Mater. 8, 282–300 (2023).
Ju, Y. et al. Anti-PEG antibodies boosted in humans by SARS-CoV-2 lipid nanoparticle mRNA vaccine. ACS Nano 16, 11769–11780 (2022).
Fadeel, B. Hide and seek: nanomaterial interactions with the immune system. Front. Immunol. 10, 133 (2019).
Dilliard, S. A., Cheng, Q. & Siegwart, D. J. On the mechanism of tissue-specific mRNA delivery by selective organ targeting nanoparticles. Proc. Natl Acad. Sci. USA 118, e2019256118 (2021).
Ngo, W. et al. Identifying cell receptors for the nanoparticle protein corona using genome screens. Nat. Chem. Biol. 18, 1023–1031 (2022).
Tang, H. et al. Cholesterol modulates the physiological response to nanoparticles by changing the composition of protein corona. Nat. Nanotechnol. 18, 1067–1077 (2023).
Lazarovits, J. et al. Supervised learning and mass spectrometry predicts the in vivo fate of nanomaterials. ACS Nano 13, 8023–8034 (2019).
Gardner, L., Kostarelos, K., Mallick, P., Dive, C. & Hadjidemetriou, M. Nano-omics: nanotechnology-based multidimensional harvesting of the blood-circulating cancerome. Nat. Rev. Clin. Oncol. 19, 551–561 (2022).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
M.M. discloses that (i) he is a co-founder and director of the Academic Parity Movement, a non-profit organization dedicated to addressing academic discrimination, violence and incivility; (ii) he is a co-founder of Targets’ Tip; and (iii) he receives royalties/honoraria for his published books, plenary lectures and licensed patent. M.H. and K.K. are inventors of granted patents describing the use of nanoparticle corona.
Supplementary information
Rights and permissions
About this article
Cite this article
Hadjidemetriou, M., Mahmoudi, M. & Kostarelos, K. In vivo biomolecule corona and the transformation of a foe into an ally for nanomedicine. Nat Rev Mater 9, 219–222 (2024). https://doi.org/10.1038/s41578-024-00658-1
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41578-024-00658-1